Best Investments for 2014
Activist investor Alex Denner is gaining an ally on Ariad's Board.,
On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow high
NPS Pharmaceuticals shares are weak Monday following a rough outing for its hormone replacement therapy Natpara at an FDA advisory panel on Friday.
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.
Language in the new Xtandi label should help Medivation and Astellas widen their market share lead over Johnson & Johnson's competing prostate cancer drug Zytiga.
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Merck will sell the skin cancer drug under the brand name Keytruda.
Under the agreement, Calico and Abbvie will work together to discover and develop new drugs for age-related diseases, including neuro-degeneration and cancer.
With Ampion failure, Ampio's pipeline is worthless.
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics
while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a
reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a
comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and
strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV